Literature DB >> 33456167

Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib.

Preston Williams1, Benjamin McKinney2.   

Abstract

Dermatomyositis is an autoimmune condition that commonly presents in the form of an overlap syndrome with other rheumatic diseases. The overlap between syndromes with highly variable symptomology makes treatment difficult. We present a case of a 39-year-old woman who presented with a facial rash, arthralgias, and lower-extremity edema and steadily progressed to develop severe proximal muscle weakness and hair loss over the course of a 2.5-month hospitalization. After diagnostic testing, she was found to have a dermatomyositis-systemic lupus erythematosus overlap syndrome. Her symptoms were refractory to initial medical management but finally resolved once she was switched to tofacitinib.
Copyright © 2020 Baylor University Medical Center.

Entities:  

Keywords:  Dermatomyositis; steroid-induced myopathy; systemic lupus erythematosus; tofacitinib

Year:  2020        PMID: 33456167      PMCID: PMC7785137          DOI: 10.1080/08998280.2020.1821589

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  9 in total

1.  Scleromyositis (scleroderma/polimyositis overlap) is an entity.

Authors:  S Jablonska; M Blaszyk
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-05       Impact factor: 6.166

2.  Guidelines of care for dermatomyositis. American Academy of Dermatology.

Authors:  L A Drake; S M Dinehart; E R Farmer; R W Goltz; G F Graham; M K Hordinsky; C W Lewis; D M Pariser; J W Skouge; S B Webster; D C Whitaker; B Butler; B J Lowery; R D Sontheimer; J P Callen; C Camisa; T T Provost; D L Tuffanelli
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

3.  Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.

Authors:  Hanxiao You; Guizhi Zhang; Qian Wang; Shangzhu Zhang; Jiuliang Zhao; Xinping Tian; Hongbin Li; Mengtao Li; Xiaofeng Zeng
Journal:  Ann Rheum Dis       Date:  2019-04-20       Impact factor: 19.103

Review 4.  JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis.

Authors:  Jared S Kahn; Sandhya Chowdary Deverapalli; David M Rosmarin
Journal:  Int J Dermatol       Date:  2018-06-05       Impact factor: 2.736

5.  Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.

Authors:  Siamak Moghadam-Kia; Devon Charlton; Rohit Aggarwal; Chester V Oddis
Journal:  Rheumatology (Oxford)       Date:  2019-06-01       Impact factor: 7.580

6.  Steroid myopathy: incidence and detection in a population with asthma.

Authors:  S L Bowyer; M P LaMothe; J R Hollister
Journal:  J Allergy Clin Immunol       Date:  1985-08       Impact factor: 10.793

7.  Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.

Authors:  K E Tymms; J Webb
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

8.  Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.

Authors:  Jürgen Wollenhaupt; Joel Silverfield; Eun Bong Lee; Jeffrey R Curtis; Susan P Wood; Koshika Soma; Chudy I Nduaka; Birgitta Benda; David Gruben; Hiroyuki Nakamura; Yoshihiro Komuro; Samuel H Zwillich; Lisy Wang; Richard J Riese
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

Review 9.  Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

Authors:  Alessia Alunno; Ivan Padjen; Antonis Fanouriakis; Dimitrios T Boumpas
Journal:  Cells       Date:  2019-08-15       Impact factor: 6.600

  9 in total
  3 in total

1.  Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.

Authors:  Carole Bitar; Thien Ninh; Katherine Brag; Soraya Foutouhi; Stella Radosta; Jade Meyers; Melody Baddoo; Delong Liu; Brittany Stumpf; Paul W Harms; Nakhle S Saba; Erin Boh
Journal:  JAMA Dermatol       Date:  2022-10-05       Impact factor: 11.816

Review 2.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28

Review 3.  Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Authors:  Kareem G Elhage; Raymond Zhao; Mio Nakamura
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.